Analyst Price Targets — KALV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 9, 2026 11:09 am | Andrew Fein | H.C. Wainwright | $37.00 | $15.82 | TheFly | KalVista price target raised to $37 from $27 at H.C. Wainwright |
| January 6, 2026 12:42 pm | — | Needham | $32.00 | $15.66 | TheFly | KalVista price target raised to $32 from $28 at Needham |
| November 11, 2025 10:50 am | — | JMP Securities | $28.00 | $10.89 | TheFly | KalVista price target lowered to $28 from $29 at Citizens JMP |
| November 5, 2024 12:09 pm | Serge Belanger | Needham | $28.00 | $11.25 | StreetInsider | Kalvista Pharmaceuticals Inc (KALV) PT Lowered to $28 at Needham |
| September 6, 2024 6:54 am | Andrew Fein | H.C. Wainwright | $20.00 | $12.87 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV) |
| September 6, 2024 6:35 am | Joseph Schwartz | Leerink Partners | $20.00 | $12.87 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Kalvista Pharmaceuticals Inc (KALV) |
| July 8, 2022 4:29 am | — | Needham | $38.00 | $10.98 | Benzinga | Needham Maintains Buy on KalVista Pharmaceuticals, Lowers Price Target to $38 |
Latest News for KALV
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted five newly-hired employees inducement options to purchase an aggregate of 66,375 shares of KalVista common stock on April 1, 2026 as inducements material to each employee entering into employment with KalVista. The options…
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new interim results from its KONFIDENT-KID clinical trial evaluating EKTERLY® (sebetralstat) for the on-demand treatment of hereditary angioedema (HAE) attacks in children ages 2-11 presented at the 2026 Global Angioedema Leadership Conference. KONFIDENT-KID is the largest pediatric trial ever…
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) shot up 8.7% on Thursday after Stifel Nicolaus raised their price target on the stock from $39.00 to $42.00. Stifel Nicolaus currently has a buy rating on the stock. KalVista Pharmaceuticals traded as high as $18.82 and last traded at $18.6350. 837,871 shares traded hands
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Friday after Stifel Nicolaus raised their price target on the stock from $39.00 to $42.00. Stifel Nicolaus currently has a buy rating on the stock. KalVista Pharmaceuticals traded as high as $19.27 and last traded at
KalVista Pharmaceuticals, Inc. (KALV) 8 Months 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KALV.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.